May 13 (Reuters) - Tvardi Therapeutics Inc TVRD.O:
TVARDI THERAPEUTICS ANNOUNCES FIRST QUARTER 2025 RESULTS AND PROVIDES BUSINESS UPDATE
TVARDI THERAPEUTICS: CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AT CLOSING ANTICIPATED TO BE SUFFICIENT TO FUND OPERATIONS INTO 2H 2026
TVARDI THERAPEUTICS: ON TRACK FOR MULTIPLE PHASE 2 DATA READOUTS WITH STAT3 INHIBITOR, TTI-101, WITH LEAD PROGRAM IN IPF EXPECTED IN 2H 2025
TVARDI THERAPEUTICS INC - COMPLETES MERGER WITH CARA THERAPEUTICS
Source text: ID:nBwbjbZ6qa
Further company coverage: TVRD.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.